Does the media refer more to CRMD or PLX?

In the previous week, CorMedix had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for CorMedix and 1 mentions for Protalix BioTherapeutics. CorMedix's average media sentiment score of 0.47 beat Protalix BioTherapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PLX or TLRY?

In the previous week, Tilray Brands had 19 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 1 mentions for Protalix BioTherapeutics. Tilray Brands' average media sentiment score of 0.61 beat Protalix BioTherapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 4 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRME or PLX?

In the previous week, Prime Medicine had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Prime Medicine and 1 mentions for Protalix BioTherapeutics. Prime Medicine's average media sentiment score of 0.44 beat Protalix BioTherapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PLX or ACRS?

In the previous week, Aclaris Therapeutics had 13 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 1 mentions for Protalix BioTherapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Protalix BioTherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protalix BioTherapeutics (PLX) Competitors

$1.97 -0.01 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 +0.01 (+0.51%)

As of 04:33 PM Eastern

Compare

PLX vs. CRMD, DSGN, TLRY, PRME, and ACRS

Should you buy Protalix BioTherapeutics stock or one of its competitors? MarketBeat compares Protalix BioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protalix BioTherapeutics include CorMedix (CRMD), Design Therapeutics (DSGN), Tilray Brands (TLRY), Prime Medicine (PRME), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Protalix BioTherapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

CorMedix presently has a consensus price target of $15.00, indicating a potential upside of 71.04%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 509.14%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

CorMedix has higher revenue and earnings than Protalix BioTherapeutics. CorMedix is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.21	$163.05M	$2.13	4.12
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94

CorMedix has a net margin of 45.25% compared to Protalix BioTherapeutics' net margin of -21.03%. CorMedix's return on equity of 45.57% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, CorMedix had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for CorMedix and 1 mentions for Protalix BioTherapeutics. CorMedix's average media sentiment score of 0.47 beat Protalix BioTherapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CorMedix beats Protalix BioTherapeutics on 13 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Design Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 54.78%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 509.14%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 1.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Very Positive
Protalix BioTherapeutics	Neutral

Protalix BioTherapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94

Design Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Summary

Design Therapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Tilray Brands?

Protalix BioTherapeutics (NYSE:PLX) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Protalix BioTherapeutics has a net margin of -21.03% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Tilray Brands	-156.51%	-3.31%	-2.42%

Protalix BioTherapeutics has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A

Protalix BioTherapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Protalix BioTherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 509.14%. Tilray Brands has a consensus price target of $11.50, indicating a potential upside of 129.08%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Tilray Brands had 19 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 1 mentions for Protalix BioTherapeutics. Tilray Brands' average media sentiment score of 0.61 beat Protalix BioTherapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	4 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Protalix BioTherapeutics and Tilray Brands tied by winning 8 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Protalix BioTherapeutics has a net margin of -21.03% compared to Prime Medicine's net margin of -4,917.55%. Protalix BioTherapeutics' return on equity of -30.89% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, Prime Medicine had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Prime Medicine and 1 mentions for Protalix BioTherapeutics. Prime Medicine's average media sentiment score of 0.44 beat Protalix BioTherapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine presently has a consensus target price of $7.65, indicating a potential upside of 182.29%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 509.14%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	105.72	-$201.14M	-$1.23	N/A
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94

Summary

Prime Medicine beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Protalix BioTherapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A

Protalix BioTherapeutics has a net margin of -21.03% compared to Aclaris Therapeutics' net margin of -832.58%. Protalix BioTherapeutics' return on equity of -30.89% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, Aclaris Therapeutics had 13 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 1 mentions for Protalix BioTherapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Protalix BioTherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Protalix BioTherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 509.14%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 180.49%. Given Protalix BioTherapeutics' higher probable upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Aclaris Therapeutics beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$158.73M	$348.49M	$6.43B	$22.82B
Dividend Yield	N/A	N/A	2.67%	4.11%
P/E Ratio	-15.15	N/A	24.46	30.13
Price / Sales	2.08	157.92	500.50	21.00
Price / Cash	17.80	22.44	42.36	23.85
Price / Book	4.19	4.71	10.43	4.59
Net Income	$8.31M	-$141.03M	$3.56B	$1.07B
7 Day Performance	0.51%	-4.41%	-1.39%	-0.60%
1 Month Performance	1.55%	-5.80%	0.86%	-1.14%
1 Year Performance	24.68%	49.25%	19.42%	18.94%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.5125 of 5 stars	$1.97 -0.5%	$12.00 +509.1%	+28.6%	$158.73M	$76.38M	N/A	200
CRMD CorMedix	3.3795 of 5 stars	$8.16 -3.5%	$15.00 +83.9%	-39.7%	$662.13M	$311.71M	3.93	30
DSGN Design Therapeutics	3.3732 of 5 stars	$10.17 -2.6%	$16.50 +62.2%	+169.8%	$654.55M	N/A	N/A	40	Positive News
TLRY Tilray Brands	3.539 of 5 stars	$5.39 -1.9%	$11.50 +113.6%	+26.1%	$642.19M	$210.48M	N/A	2,842	Trending News
PRME Prime Medicine	2.1902 of 5 stars	$3.19 -6.3%	$7.65 +140.2%	N/A	$641.19M	$4.63M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Protalix BioTherapeutics compare to CorMedix?

Summary

How does Protalix BioTherapeutics compare to Design Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Tilray Brands?

Summary

How does Protalix BioTherapeutics compare to Prime Medicine?

Summary

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Protalix BioTherapeutics compare to CorMedix?

Do analysts rate CRMD or PLX?

Which has more volatility & risk, CRMD or PLX?

Which has preferable valuation and earnings, CRMD or PLX?

Is CRMD or PLX more profitable?

Does the media refer more to CRMD or PLX?

Do institutionals and insiders believe in CRMD or PLX?

Summary

How does Protalix BioTherapeutics compare to Design Therapeutics?

Which has more risk and volatility, DSGN or PLX?

Do analysts recommend DSGN or PLX?

Do institutionals & insiders believe in DSGN or PLX?

Does the media favor DSGN or PLX?

Which has better valuation & earnings, DSGN or PLX?

Is DSGN or PLX more profitable?

Summary

How does Protalix BioTherapeutics compare to Tilray Brands?

Is PLX or TLRY more profitable?

Which has preferable earnings & valuation, PLX or TLRY?

Which has more risk & volatility, PLX or TLRY?

Do analysts rate PLX or TLRY?

Does the media refer more to PLX or TLRY?

Do institutionals & insiders believe in PLX or TLRY?

Summary

How does Protalix BioTherapeutics compare to Prime Medicine?

Is PRME or PLX more profitable?

Does the media favor PRME or PLX?

Do analysts recommend PRME or PLX?

Which has more risk & volatility, PRME or PLX?

Do insiders & institutionals believe in PRME or PLX?

Which has higher valuation and earnings, PRME or PLX?

Summary

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Which has more volatility and risk, PLX or ACRS?

Which has stronger valuation and earnings, PLX or ACRS?

Is PLX or ACRS more profitable?

Does the media refer more to PLX or ACRS?

Do insiders and institutionals believe in PLX or ACRS?

Do analysts rate PLX or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools